Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials

Cell Stress and Chaperones(2024)10.1016/j.cstres.2024.08.002Source: DataRank Database

Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials is a research paper published in Cell Stress and Chaperones (2024). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 2.22)OA: goldTopics (30)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Xin Tang ORCID,David T. Woodley ORCID,Mei Chen ORCID,Wei Li ORCID,Cheng Chang ORCID

Live enrichment

PubMed:39181529 PMC:PMC11402043 OpenAlex:https://openalex.org/W4401800053

National Institutes of Health

Grant: GM067100

NIGMS NIH HHS

Grant: R01 GM067100

National Institutes of Health

Grant: 5R01GM067100-04

Mechanisms of Human Dermal Fibroblast Migration

Congressionally Directed Medical Research Programs

FWCI

2.22

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.cstres.2024.08.002

GOLDhttps://doi.org/10.1016/j.cstres.2024.08.002

publisherhttps://doi.org/10.1016/j.cstres.2024.08.002

publisherhttps://api.elsevier.com/content/article/PII:S1355814524001135?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1355814524001135?httpAccept=text/plain

Fields of Study

Heat shock proteins researchATP Synthase and ATPases ResearchMedicine03 medical and health sciences0302 clinical medicineHumansHSP90 Heat-Shock ProteinsNeoplasmsAntineoplastic AgentsClinical Trials as Topic

MeSH Terms

Antineoplastic AgentsClinical Trials as TopicHumansNeoplasmsHSP90 Heat-Shock Proteins

Keywords

Clinical trialMedicineCancerIntensive care medicineInternal medicineHuman organsClinical TrialsHsp90 InhibitorsHsp90 ChaperonesClinical Trials as TopicNeoplasmsHumansAntineoplastic AgentsReview ArticleHSP90 Heat-Shock Proteins

Sustainable Development Goals

SDG 0: Good health and well-being

Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials

FAIR Checklist

Authors (5)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)